Foundation Medicine and Day One Biopharmaceuticals Form Collaboration Focused on Pediatric Cancer Care - The Cancer Letter

Foundation Medicine and Day One Biopharmaceuticals Form Collaboration Focused on Pediatric Cancer Care – The Cancer Letter

Foundation Medicine Inc., a pioneer in cancer molecular profiling, and Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people with life-threatening diseases, have formed a collaboration to develop FoundationOne CDx as a diagnostic companion for Day One’s lead investigational treatment, DAY101 (tovorafenib).

To access this subscriber-only content, please login or renew your subscription.

Are you looking for an IP connection? Our IP connection system is now automatic. If your institution has a site license, please connect from the site or through your VPN to access this content.

Login Register

#Foundation #Medicine #Day #Biopharmaceuticals #Form #Collaboration #Focused #Pediatric #Cancer #Care #Cancer #Letter

Leave a Comment

Your email address will not be published.